(WISH) – The United States of Appeals ruled in Eli Lilly’s favor for the validity and infringement of the Alimta vitamin regimen patent, Jane King at the Nasdaq reports.
According to a release from Eli Lilly, the announcement of the court’s ruling was made on Jan. 12.
“The ruling declared the vitamin regiment patent is valid and would be infringed by the generic challengers’ proposed products,” the release stated.
The U.S. Court for the Southern District of Indiana ruled in Lilly’s favor about the matter in both March 2014 and August 2015.
“We are please with today’s rulings by the Court of Appeals, affirming the earlier district court’s decisions, finding the Alimat vitamin regimen patent is valid and would be infringed,” said Michael J. Harrington, senior vice president and general counsel for Lilly. “The significant scientific research that Lilly performed in support of the vitamin regimen patent deserves intellectual property protection, which has been confirmed in every validity challenge to date. We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights help support the development of the next generation of innovative medicines to treat unmet medical needs.”
In other business headlines, a new large study affirms the medical uses for marijuana. The study is 400 pages.
It was released by the National Academies of Science, Engineering, and Medicine.
It is a comprehensive study of current scientific knowledge of medical cannabis and it found that it can effectively treat some patients of chronic pain.
It was found to be particularly effective in treating multiple sclerosis and reduces the nausea associated with chemotherapy treatments.
For more business headlines from Jane King at the Nasdaq, watch Daybreak Monday through Friday.